From Acute Infection to Chronic Symptoms
Post-infectious IBS (PI-IBS) describes the development of IBS symptoms — abdominal pain, bloating, and altered bowel habits meeting Rome criteria — following an episode of acute infectious gastroenteritis. It is one of the best-documented examples of how a time-limited insult can produce lasting changes in gut function. Meta-analyses estimate that approximately 10–15% of individuals who recover from bacterial gastroenteritis (caused by Campylobacter, Salmonella, Shigella, or E. coli) go on to develop IBS symptoms that persist for months or years.
Mechanisms of Persistence
Several overlapping mechanisms explain why symptoms outlast the original infection:
Persistent low-grade mucosal inflammation: Mucosal biopsies from PI-IBS patients show increased intraepithelial lymphocytes, mast cells, and enterochromaffin cells even after pathogen clearance. These residual immune changes maintain visceral hypersensitivity.
Enteric nervous system remodelling: Acute inflammation triggers neuroplastic changes in the ENS — increased nerve-fibre density, altered neurotransmitter expression, and heightened excitability of afferent neurons. These changes can persist long after inflammation resolves.
Microbiome disruption: Acute infection, often followed by antibiotic treatment, reduces microbial diversity and alters community structure. Decreased butyrate-producing taxa and increased Proteobacteria may impair barrier function and perpetuate immune activation.
Increased intestinal permeability: Tight-junction protein downregulation during acute infection may not fully recover, allowing continued translocation of luminal antigens into the mucosa.
Psychological amplification: The distressing experience of acute gastroenteritis, particularly when severe or prolonged, can generate health anxiety and hypervigilance toward gut sensations — reinforcing the gut–brain feedback loop described in IBS pathophysiology.
Risk Factors
Not everyone who contracts gastroenteritis develops PI-IBS. Identified risk factors include: severity and duration of the initial infection (particularly if hospitalisation was required); female sex; younger age at infection; pre-existing anxiety or depression; antibiotic use during the acute episode; and infection with toxigenic strains. These risk factors suggest a convergence of biological vulnerability and environmental exposure.
Prognosis and Management
The encouraging news is that PI-IBS has a better prognosis than non-PI IBS. Longitudinal studies show that approximately 50% of PI-IBS patients experience significant symptom improvement within 5 years, compared with lower remission rates in idiopathic IBS. Management follows standard IBS principles — dietary modification (low-FODMAP), antispasmodics, gut-directed psychotherapy — with emerging interest in targeted probiotic strains and mucosal-healing strategies. Crucially, patients benefit from understanding the biology: their symptoms are not imagined, they are a documented post-infectious sequela with identifiable mechanisms and a trajectory toward improvement.